Victory Capital Management Inc. Has $3.30 Million Holdings in Organon & Co. (NYSE:OGN)

Victory Capital Management Inc. lifted its holdings in Organon & Co. (NYSE:OGN) by 20.7% in the 4th quarter, Holdings Channel reports. The firm owned 221,278 shares of the company’s stock after buying an additional 37,980 shares during the quarter. Victory Capital Management Inc.’s holdings in Organon & Co. were worth $3,301,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Pacer Advisors Inc. lifted its position in Organon & Co. by 94,482.1% during the 4th quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock worth $166,391,000 after acquiring an additional 11,140,388 shares during the last quarter. Geode Capital Management LLC increased its stake in Organon & Co. by 2.0% in the third quarter. Geode Capital Management LLC now owns 4,248,108 shares of the company’s stock valued at $81,288,000 after acquiring an additional 82,220 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Organon & Co. by 0.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,333,703 shares of the company’s stock valued at $49,739,000 after acquiring an additional 10,652 shares during the period. Thompson Siegel & Walmsley LLC grew its stake in Organon & Co. by 6.4% during the third quarter. Thompson Siegel & Walmsley LLC now owns 2,262,379 shares of the company’s stock worth $43,279,000 after buying an additional 136,457 shares during the last quarter. Finally, Private Management Group Inc. grew its stake in Organon & Co. by 11.9% during the fourth quarter. Private Management Group Inc. now owns 2,119,288 shares of the company’s stock worth $31,620,000 after buying an additional 225,420 shares during the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on OGN shares. TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Barclays dropped their price objective on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Finally, Morgan Stanley lowered their price target on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $20.80.

Organon & Co. Price Performance

Organon & Co. stock opened at $15.34 on Monday. The stock’s fifty day moving average price is $15.46 and its two-hundred day moving average price is $16.64. Organon & Co. has a one year low of $13.87 and a one year high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The firm has a market cap of $3.96 billion, a PE ratio of 4.61, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. As a group, research analysts expect that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.30%. The ex-dividend date was Monday, February 24th. Organon & Co.’s dividend payout ratio is 33.63%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.